



100 | CEO Leaders in STEM

a publication by STEMconnector®





Robert A. Bradway

Chairman and Chief Executive Officer Amgen

Amgen discovers, develops, manufactures, and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

Robert A. Bradway is Amgen's chairman and chief executive officer. Bradway became chairman in January 2013 and chief executive officer in May 2012. Bradway served as the company's president and chief operating officer from May 2010 to May 2012 and was appointed to the Amgen Board of Directors in October 2011. He joined the company in 2006 as vice president, Operations Strategy, and served as executive vice president and chief financial officer from April 2007 to May 2010. Prior to joining Amgen, he was a managing director at Morgan Stanley in London where he had responsibility for the firm's

banking department and corporate finance activities in Europe. Bradway joined Morgan Stanley in New York as a health care industry investment banker in 1985 and moved to London in 1990 where he served as head of the firm's international health care investment banking activities until assuming broader corporate finance management responsibilities. Bradway holds a bachelor's degree in biology from Amherst College and a master's degree in business administration from Harvard University. He is a member of the board of directors of Norfolk Southern Corporation.

The story of Amgen began with a very simple hypothesis: that emerging research in genetics could lead to very exciting opportunities if the right scientists could be assembled and given the appropriate resources. More than three decades ago, a small group of visionary investors and pioneering scientists came together in an effort to push the boundaries of scientific discovery and imagine a future that few others could see at the time. Amgen has since grown to become the world's largest biotechnology company, having served more than 25 million patients with its medicines. As a company, we could not have accomplished what we have were it not for our commitment to build a culture that embraces science and innovation—a culture that continues to shape who we are today.

Throughout history, advances in science and technology have led to countless far-reaching benefits, including increased efficiencies, greater societal prosperity, and dramatic improvements in human health and well-being. Many of those advances came about due to significant financial investments in innovation and through the passion of scientists willing to challenge conventional thought in a particular technical area. The danger we face today is the possibility that fewer people will enter highly technical fields in the decades ahead, at a time when demand for individuals with these kinds of skills is on the rise.

As Chairman and Chief Executive Officer at Amgen, a company that employs thousands of scientists in its effort to discover, develop, manufacture, and deliver medicines, I know what can be achieved when investments are made in science—and in scientists. I've seen the lives of patients transformed as a result of new medicines we've discovered, developed and manufactured—and I've seen the unrelenting passion of scientists who work on those kinds of therapies. It's shown me how rewarding it can be to pursue science as a career—and the broad-based benefits that science, technology, engineering, and math (STEM) disciplines can provide.

Amgen and the Amgen Foundation, our primary philanthropic arm, have committed more than \$70 million in advancing STEM education in meaningful ways across the United States and Europe. Amgen's Biotechnology Lab Program has reached more than 250,000 students with real-world biotech lab experiences run by science teachers in their own classrooms. By providing advanced biotech curricula and loaning professional-grade lab equipment to schools for free, we open students' eyes to the world of biotechnology with lab experiences designed to ignite a deep passion for scientific discovery.

At the higher education level, the Amgen Scholars Program continues to provide undergraduates the opportunity to undertake a summer research experience at many of the world's leading universities. Seven years into the program, more than 85 percent of program alumni who have graduated from college are now pursuing advanced degrees or careers in scientific fields.

We also partner with other public and private stakeholders in this important space. One example is our recent \$1 million commitment to 100Kin10, a multi-sector mobilization led by the Carnegie Corporation to strategically address the nation's shortage of STEM teachers, and to improve STEM learning for all students by training 100,000 excellent science, technology, engineering, and math teachers over the next decade.

In the years and decades ahead, we will continue to face many challenges as a society—challenges that will require passionate scientists and engineers capable of applying their knowledge and expertise in new ways to advance our present understanding across multiple technical disciplines. For example, despite the great progress we have made in the past century in the field of medicine, millions continue to suffer from grievous illnesses around the world. That is why we at Amgen take our investments in science education so seriously and encourage others to join this important effort. ■

“I know what can be achieved when investments are made in science—and in scientists.”